By vgreene, 9 October, 2014 Patient Type Header (Long) Adolescents Does this Patient Type contain sub types? No Patient Type Details Current data on efficacy/safety of PrEP in adolescents are insufficient. Weigh risks and benefits of PrEP carefully in context of local laws/regulations about autonomy in healthcare decision-making by minors [IIIB]. epocrates note: Since this CDC guideline was issued, the FDA has approved the use of TDF/FTC in combo w/ safer sex practices to reduce the risk of sexually acquired HIV-1 (PrEP) in adolescents weighing at least 35 kg.